Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
Adial Pharmaceuticals, IncJuly 14, 2021 GMT
Data merits further testing for pain reduction as a possible alternative to opioids
Validation of Purnovate acquisition
CHARLOTTESVILLE, Va., July 14, 2021 (GLOBE NEWSWIRE) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced advancements related to its adenosine analog development platform being developed by Purnovate, Inc., a division of Adial Pharmaceuticals, Inc.
Key highlights:
Compounds have been developed that are potent against specifically targeted adenosine receptors while being selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects that can be problematic for many therapeutic indica
AgriFORCE Growing Systems Announces Appointment of Highly Acclaimed Accounting and Business Advisory Executive, Richard Levychin, to Board of Directors
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Adial Announces Positive Pre-C - GuruFocus com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.